153P Safety/tolerability and antitumor activity of sitravatinib plus tislelizumab (TIS) in patients with advanced platinum-resistant ovarian cancer (PROC)JC Goh, Michael Millward, Mark Voskoboynik et al.|Annals of Oncology|2021Cited by 3
1280P Sitravatinib + tislelizumab in patients with metastatic non-small cell lung cancer (NSCLC)Qing Zhou, Yi‐Long Wu, Xianjun Yu et al.|Annals of Oncology|2021Cited by 2